When was BioGenomics founded?

BioGenomics was founded in 2002 and raised its 1st funding round 20 years after it was founded.

Where is BioGenomics located?

BioGenomics is headquartered in Thane, India. It is registered at 1-A,Valliamal Road, Opp. Seventh Day Adventist School, Vepery, CHENNAI , Unclassified TN 600007.

Who is the current CEO of BioGenomics?

Sanjay Sonar of BioGenomics. They have also founded 1 company.

Which legal entities is BioGenomics associated with?

BioGenomics is associated with Biogenomics Limited and 1 other.

How many employees does BioGenomics have?

As of Mar 31, 2026, the latest employee count at BioGenomics is 147.

Is BioGenomics a funded company?

BioGenomics is a funded company, having raised a total of $44.9M across 3 funding rounds to date. The company's 1st funding round was a $***** Series B round, raised on Jan 11, 2022.

How much is BioGenomics worth?

The latest valuation of BioGenomics is ₹***** as of May 26, 2024.

When was the latest funding round of BioGenomics?

BioGenomics' latest funding was a $***** Series B round on May 26, 2024, with participation from 1 investor.

What is the annual revenue of BioGenomics?

Annual revenue of BioGenomics is between ₹10 Cr and ₹50 Cr as on Mar 31, 2025

Where does BioGenomics rank among its competitors?

BioGenomics ranks 800th amongst 3530 active competitors, of which 1196 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of BioGenomics?

BioGenomics' top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

BioGenomics - 2026 Company Profile, Team, Funding, Competitors & Financials

BioGenomics is a series B company based in Thane (India), founded in 2002 by Sanjay Sonar. It operates as a Manufacturer of biopharmaceutical products focused on diabetes and cancer treatments. BioGenomics has raised $44.9M in funding from Oman Investment Authority and Eagle Asia Holding, with a current valuation of ₹*****. The company has 3530 active competitors, including 1196 funded and 823 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.

Company Details

Manufacturer of biopharmaceutical products focused on diabetes and cancer treatments. The company develops innovative technologies and processes for the production of recombinant proteins and biosimilars. Operations include research and development, clinical studies, and manufacturing within compliant facilities. The business focuses on creating high quality medicines through advanced infrastructure and scientific expertise.

Website: biogenomics.co.in
Email ID: *****@biogenomics.co.in
Phone Number: +91 **********
Registered Address: 1-A,Valliamal Road, Opp. Seventh Day Adventist School, Vepery, CHENNAI , Unclassified TN 600007

Key Metrics

Founded Year

2002

Location

Thane, India

Stage

Series B

Total Funding

$44.9M in 3 rounds

Latest Funding Round

Series B, May 26, 2024, $*****

Post Money Valuation

₹***** as on May 26, 2024

Investors

Oman Investment Authority & 1 more

Ranked

800^th among 3530 active competitors

Annual Revenue

₹10 - ₹50 Cr as on Mar 31, 2025

Employee Count

147 as on Mar 31, 2026

Similar Companies

Jazz Pharmaceuticals & 3273 more

View BioGenomics' full profile

BioGenomics is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
BIOGENOMICS LIMITED CIN: U24234PY2002PLC009158 , India, Active	Apr 24, 2002	₹10 - ₹50 Cr (As on Mar 31, 2025)	147 (As on Mar 31, 2026)
Biogenomics Limited CIN: U24234TN2002PLC048821 , India, Active	Apr 23, 2002	₹10 - ₹50 Cr (As on Mar 31, 2025)	141 (As on Aug 01, 2025)

BioGenomics has raised a total funding of $44.9M over 3 rounds. Its first funding round was on Jan 11, 2022. Its latest funding round was a Series B round on May 26, 2024 for $*****. 1 investor participated in its latest round. BioGenomics has 2 institutional investors.

Here is the list of recent funding rounds of BioGenomics:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 26, 2024	7174547	Series B	4318742	1113018	3408440	2588973
Jul 03, 2022	2733680	Series B	3349212	2298621	2895304	2341880
Jan 11, 2022	4658936	Series B	8898246	5357984	Eagle Asia Holding	1351415

Access funding benchmarks and valuations. Sign up today!

View details of BioGenomics's funding rounds and investors

The founders of BioGenomics is Sanjay Sonar.

Here are the details of BioGenomics' key team members:

Sanjay Sonar: Co-Founder & Owner & President & CEO of BioGenomics.
Contact Info: 1 email address and 1 phone number

BioGenomics' Board of Directors

BioGenomics's board has 9 active members. Pushkar Jauhari, Ali Abdullah Ali Al Aamri, Mohammed Hamdan Saif Al Rubaie and Archana Krishnan are part of team and Imran Jamiluddin Shaikh, Rajesh Shashikant Dalal, Ammar Abdullah Hamad Al Ali, Namit Rustagi and Rajiv Malik are independent board members.

Here is the list of BioGenomics' board of directors:

Name	Type	Representing	Status	Duration
Archana Krishnan	Team	-	Current	20y 8m
Pushkar Jauhari	Investor	-	Current	4y 3m
Ali Abdullah Ali Al Aamri	Investor	-	Current	4y 4m
hpojgzs	Investor	hvnaqsn	Current	7y 4m
Imran Jamiluddin Shaikh	Independent board member	-	Current	2y 1m
jqflgao	Independent board member	-	Current	2y 9m
adbexpf	Independent board member	-	Current	8y 4m
iczxuud	Independent board member	-	Current	4y 5m
omdkvts	Independent board member	-	Current	3y 4m

View details of BioGenomics's Founder profiles and Board Members

BioGenomics' employee count trend

BioGenomics has 147 employees as of Mar 26. The total employee count is 75.0% more than what it was in Mar 25. Here is BioGenomics's employee count trend over the years:

Uncover BioGenomics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of BioGenomics include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of BioGenomics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	72/100
9th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, Khosla Ventures & 23 others	72/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
800th	BioGenomics 2002, Thane (India), Series B	Manufacturer of biopharmaceutical products focused on diabetes and cancer treatments	$44.9M	Oman Investment Authority & 1 others	50/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on BioGenomics's competitors? Click here to see the top ones

Founders own 2.36%, Parent Entities own 34.12%, Enterprises (largest shareholder) own 51.88% and Other People own 9.64%. The net worth of BioGenomics's founders is INR 18.1Cr as of May 26, 2024.

Shareholders Name	Post Round Holding %	Net worth	Cumulative Investment	Realised Returns	Unrealised Returns	Return Multiple
Founder	2.36%	18.1Cr	37	80	88	29
Sanjay Sonar	6	8	3	4	1	6
Parent Entity	34.12%	262Cr	1146298	8848039	9022382	4989675
Enterprise	51.88%	399Cr	7728358	2965800	9172745	8893652
Other People	9.64%	74.1Cr	9823067	9411185	6699769	8499111
ESOP Pool	2.00%	15.4Cr	5	1	4	1
Total	100.00%	769Cr	2825745	9407418	8956053	5529328